What are the manufacturers of palbociclib/palbociclib?

Palbociclib/Pabociclib, as an important anti-cancer drug for locally advanced or metastatic breast cancer, is particularly suitable for patients with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-). With its widespread use around the world, there are currently multiple manufacturers on the market providing this drug, including both original drugs and generic drugs.

Pfizer Inc. of the United States (Pfizer Inc.), as the original drug manufacturer of palbociclib, enjoys a high reputation worldwide. Palbociclib developed by the company, under the trade name "Ibrance", has become an important drug in the field of breast cancer treatment since it was approved by the U.S. Food and Drug Administration (FDA) in 2015. The mechanism of action of palbociclib is that it is a first-in-class, highly selective cyclin-dependent kinase4/6 inhibitor that can effectively block the activity of cyclin-dependent kinase (CDK) 4 and 6, thereby slowing down the proliferation of HR-positive breast cancer cells.

With the gradual liberalization of patent protection, in addition to original drug manufacturers, many pharmaceutical companies have also begun to get involved in the production of generic drugs of palbociclib. At present, domestic companies such as Qilu Pharmaceutical have successfully obtained marketing approval for generic drugs. At the same time, Incepta Pharmaceuticals of Bangladesh, ASEAN Pharmaceuticals of Laos, and Everest Pharmaceuticals of Bangladesh have also launched more affordable versions of generic drugs. Although the price has been reduced, these generic drugs remain consistent with the original drugs in terms of drug ingredients, providing patients with more diverse medication options.